Ginkgo Bioworks Holdings Pre-Tax Profit Margin 2020-2023 | DNA
Ginkgo Bioworks Holdings pre-tax profit margin from 2020 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Ginkgo Bioworks Holdings Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2023-03-31 |
$0.39B |
$-1.73B |
-444.62% |
| 2022-12-31 |
$0.48B |
$-2.12B |
-444.86% |
| 2022-09-30 |
$0.53B |
$-3.54B |
-671.54% |
| 2022-06-30 |
$0.54B |
$-2.97B |
-551.58% |
| 2022-03-31 |
$0.44B |
$-2.36B |
-538.13% |
| 2021-12-31 |
$0.31B |
$-1.84B |
-585.67% |
| 2021-06-30 |
$0.10B |
$-0.16B |
-154.46% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.379B |
$0.478B |
|
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
|
